Skip to content

Sensitization Potential Evaluation - BARZILAI

Evaluation Of The Primary And Accumulated Dermal Irritation Potential And Sensitization Of An Investigational Product - ID27568

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
REBEC
Registry ID
RBR-8sv755
Enrollment
Unknown
Registered
2020-06-03
Start date
2020-09-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disturbances of skin sensation

Interventions

After signing the Free and Informed Consent Form, the research participants will be submitted to individual clinical evaluation to check the inclusion and non-inclusion criteria by the dermatologist,
E05.318.370.800

Sponsors

INFAN - Indústria Química e Farmacêutica Nacional
Lead Sponsor
INFAN - Indústria Química e Farmacêutica Nacional
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Participants of both sexes; Age between 18 to 70 years; Phototypes: I, II, III and IV (according to an adapted Fitzpatrick scale - Annex 1); Skin of the whole test region; Agreement to obey the trial procedures and attend the clinic on the days and times determined for medical evaluations and for application and reading of the dressings; Understand, consent and sign the Free and Informed Consent Form (ICF).

Exclusion criteria

Exclusion criteria: Pregnancy or risk of pregnancy and / or lactation; (when women); Background atopic or allergic to health products; Use of anti-inflammatory drugs 30 days and / or immunosuppressive for up to three months before selection; Diseases that cause suppression of immunity, such as diabetes and HIV; Personal history of atopy; Intense sun exposure or tanning sessions up to 15 days before the evaluation; Prediction of intense exposure to sunlight or tanning sessions during the study period; Prediction of sea baths, pool or sauna during the study; Water sports practice during the study; Dermographism (property that has the skin of certain individuals to swell and redden in the place where it is streaked by something relatively sharp); Use of oral or topical treatment with vitamin A acid and / or its derivatives up to 1 month before the beginning of the study; Aesthetic and / or dermatological treatment on the body within 03 weeks before selection; Vaccination scheduled during the study period or up to 03 weeks before selection; History of sensitization and irritation to a topical product; Active skin pathologies (local and / or disseminated) that may interfere with the results of the study; Use of new drugs, health products that are not part of the participant's routine during the study; Skin reactivity; Previous participation in studies with the same product; Known history or suspected intolerance to any ingredient in the study products (test or comparative products); History of lack of adherence or unwillingness to adhere to the study protocol; Other conditions considered by the evaluating physician as reasonable for the disqualification from participation in the study.

Design outcomes

Primary

MeasureTime frame
No appearance of skin sensitivity is expected after application of the product in 85% of patients

Secondary

MeasureTime frame
Secondary outcomes are not expected

Countries

Brazil

Contacts

Public ContactMarcelo Oliveira

INFAN - Indústria Química e Farmacêutica Nacional

marcelo.alvaro@hebron.com.br+55 (81) 3722-1333

Outcome results

None listed

Source: REBEC (via WHO ICTRP)